Welcome to our dedicated page for Galectin Therapeutics SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galectin Therapeutics Inc. (NASDAQ: GALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer, Galectin Therapeutics uses these filings to report on its financial condition, clinical development activities, governance, and capital structure.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, including its focus on galectin-targeted therapeutics and the belapectin program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension. Current reports on Form 8-K highlight material events such as clinical data disclosures, new or supplemental lines of credit, changes to compensation arrangements, and the posting of updated corporate presentations.
Proxy materials, including definitive proxy statements on Schedule 14A, describe items submitted to stockholders, such as director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. These documents also outline aspects of corporate governance, board structure, and equity compensation.
Through this page, users can also monitor filings that relate to financing arrangements, including convertible promissory notes and warrants, which may affect Galectin Therapeutics’ capital resources and potential dilution. Real-time updates from EDGAR are paired with AI-powered summaries that highlight key points in lengthy reports, helping readers quickly identify information on topics such as the NAVIGATE trial, belapectin’s regulatory status, and risk factor disclosures.
For those researching GALT, this filings archive offers a structured view of the company’s official disclosures, from financial reporting to governance decisions, with tools to make complex regulatory documents easier to understand.
Galectin Therapeutics Inc. director and more than 10% owner associated with 10X Fund, L.P. reported recent changes in holdings. On 11/24/2025, 24,000 shares of common stock were transferred in an in-kind distribution to a withdrawing limited partner of 10X Fund, L.P., with no consideration received, which is described as exempt from short-swing profit rules. On 12/16/2025, 30,681 common shares were sold in multiple transactions at a weighted average price of
Galectin Therapeutics director Jack W. Callicutt reported option exercises and related stock sales under a Rule 10b5-1 trading plan adopted on August 29, 2025. On December 12, 2025, he exercised stock options to acquire 19,793 common shares at an exercise price of $4.16 and sold 19,793 shares at a weighted average price of $6.274, leaving 11,206 shares held directly.
On December 15, 2025, he exercised options to acquire 8,417 shares at $4.16 and sold 8,417 shares at a weighted average price of $6.3, with 11,206 Galectin Therapeutics shares shown as beneficially owned directly after the reported transactions. The options exercised have a $4.16 exercise price, vested 25% on June 30, 2018, 25% on September 30, 2018, and 50% on December 31, 2018, and expire on May 22, 2028.
Galectin Therapeutics Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 3, 2025. Stockholders elected all nominated directors to serve until the next annual meeting or until their successors are elected and qualified, with each nominee receiving more votes for than withheld.
Stockholders approved a non-binding advisory resolution on executive compensation, with 25,260,489 votes for, 639,415 against and 310,420 abstentions, alongside 19,513,532 broker non-votes. In a separate advisory vote on how often to hold future say-on-pay votes, 22,075,944 votes favored a three-year frequency, and the Board determined that advisory votes on named executive officer compensation will be held every three years. Stockholders also ratified the selection of Cherry Bekaert LLP as the company’s independent registered public accounting firm for the year ending December 31, 2025, with 45,458,024 votes for, 142,268 against and 123,564 abstentions.
Galectin Therapeutics Inc. (GALT) reported insider transactions by its President and CEO, who is also a director. On November 17, 2025, the executive exercised stock options to buy 15,680 shares of common stock at $2.39 per share and sold the same number of shares at a weighted average price of $6.0359. On November 18, 2025, the executive similarly exercised options for 6,783 shares at $2.39 and sold those shares at a weighted average price of $6.1511. After these transactions, the executive directly owned 832,592 common shares and indirectly held 2,000 shares as custodian for a minor child. The filing notes that the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on April 17, 2025, and that the options exercised had vested fully on December 14, 2018.
Galectin Therapeutics Inc. (GALT) CFO Jack W. Callicutt reported multiple option exercises and related stock sales. On November 17 and 18, 2025, he exercised several stock options to buy common shares at exercise prices of
Sale prices were reported as weighted averages of about
Galectin Therapeutics Inc. filed an 8-K stating it furnished a press release with results of operations and financial condition for the nine months ended September 30, 2025, along with a business update. The information under Item 2.02 is furnished, not filed, and the press release is attached as Exhibit 99.1 dated November 14, 2025.
Galectin Therapeutics (GALT) filed its Q3 2025 10‑Q, reporting a net loss of
Cash and equivalents were
Total assets were
Galectin Therapeutics (GALT) CEO and Director reported a Rule 10b5-1 trade. On 11/10/2025, he exercised 1,867 stock options at $2.39 and sold 1,867 common shares at a weighted average price of $6.0269 (sales ranged from $6.00 to $6.12). The exercised options were granted on 12/14/2018 and vested 100%.
Following the transactions, he beneficially owns 832,592 shares directly, plus 2,000 shares indirectly as custodian for a minor child. He also reports 22,363 derivative securities (options) beneficially owned.
Galectin Therapeutics (GALT) CFO Jack W. Callicutt reported option exercises and same‑day sales on 11/10/2025 under a Rule 10b5‑1 plan adopted on April 17, 2025. He exercised stock options for 5,291 shares (strike prices: $1.11, $1.23, and $1.98) and sold the same number of shares in open‑market transactions.
Sales were executed at weighted average prices of $6.022, $6.0266, and $6.0298, with individual trades ranging from $6.00 to $6.14. Following these transactions, he directly owned 7,614 shares of common stock.
Galectin Therapeutics (GALT) reported that it presented results from its NAVIGATE trial at the AASLD 2025 Annual Meeting and posted an updated Corporate Presentation. The company also issued a press release; both materials were provided as Exhibits 99.1 and 99.2.
The materials were furnished under Item 7.01 of a Form 8-K and are not deemed filed under the Exchange Act. The disclosures include forward-looking statements subject to the cautionary notes in the exhibits and other SEC reports.
FAQ
What is the current stock price of Galectin Therapeutics (GALT)?
What is the market cap of Galectin Therapeutics (GALT)?
